ClinicalTrials.gg
RecruitingNCT05759117Updated Sep 1, 2026

Prospective Evaluation of Patients With Pleural Effusion

An observational study in Pleural Effusion, sponsored by Chinese University of Hong Kong. Recruiting at 2 sites in Hong Kong. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-01.

Sponsored by Chinese University of Hong Kong · Observational

From the registry’s dates

  • Started Sep 2022; still recruiting 4 years 2 months later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,000
Ages
18 Years and older
Sex
All
01

Study summary

Having a pleural effusion is a common reason for being hospitalized, as it usually requires in-patient care for invasive diagnostic and therapeutic procedures. Specific subtypes of pleural effusion may warrant recurrent admissions, a longer hospital stay and consume more healthcare resources. Despite the recent advancement of pleural medicine, better research is increasingly desired to fill the gaps in establishing an early diagnosis and optimal management of pleural effusion from various causes. Local data on different aspects of pleural effusion is also lacking.

Read the detailed description

The aetiologies of pleural effusion range from cardio-respiratory diseases, malignancy, infection to systemic inflammatory conditions. However, data on the exact incidence of individual causes of pleural effusion is inadequate. Conflicting results on the aetiologies of pleural effusion were shown in several retrospective and prospective studies based in different geographical regions, which may be explained by the different epidemiology of common diseases in the corresponding areas and patients recruited. Despite a common clinical problem, the incidence and aetiology of pleural effusion have not been examined on a population level in Hong Kong. Therefore, a local study is necessary to inform physicians about the disease burden of pleural effusion.

The management of pleural disease can be heterogeneous, as reflected by a recent multi-institutional questionnaire study in Hong Kong. Infrequent updates of international guidelines of pleural medicine, lack of an established registry reflecting the patient burden, procedure load and complications may contribute. Delayed or suboptimal management of pleural diseases can lead to unnecessary invasive procedures, prolonged hospital stays and even higher mortality rates. A local registry should be established to stocktake and understand diagnostic accuracy and complication rates of pleural procedures and reflects the real-life practice by hospital physicians.

This prospective study aims at evaluating the aetiology and management of pleural diseases prospectively. The management by the attending doctors will not be interfered. Recruited patients will be divided into subgroups based on their characteristics for further analysis. The data collected from this study will guide the planning of subsequent research to overcome the knowledge and service gap in managing pleural diseases.

02

Conditions studied

  • Pleural Effusion

Browse trials for

03

In context

Pleural Effusion

241 studies on the registry are indexed under Pleural Effusion; 50 are open to participants now.

This study's planned enrollment of 1,000 is above the median of 140 across 93 observational studies indexed under Pleural Effusion.

Browse Pleural Effusion studies →

Lead sponsor

Chinese University of Hong Kong is the lead sponsor of 1,454 studies on the registry; 474 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients who have pleural effusion and will undergo thoracentesis for pleural fluid sampling

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients hospitalized for pleural effusion.
  • Pleural tapping will be performed for pleural fluid analysis.
  • Aged 18 years old or above

Exclusion criteria

Exclusion Criteria:

- Failed to obtain due to the patient's refusal or cognitive impairment

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,000 participants (estimated)
Target follow-up
1 Month
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • Pleural effusion

    All patients with pleural effusion who will undergo thoracentesis

    Procedure: thoracentesis

Interventions

  • Procedurethoracentesis

    A type of pleural procedure that will yield pleural fluid for subsequent analysis

    Also known as: chest drain insertion

06

What researchers measure

Primary outcomes

  1. Aetiology of pleural effusion

    spectrum of aetiology for pleural effusion

    Time frame: 1 month

Secondary outcomes

  1. Management of pleural effusion

    common clinical practice of handling pleural effusion will be evaluated

    Time frame: 1 month

  2. Prognosis of pleural effusion

    need for hospitalization, pleural procedure, complication rate and time required to establish a diagnosis for patients with pleural effusion will be evaluated

    Time frame: 1 month

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05759117
Responsible party
Ka Pang Chan (Clinical Lecturer, Chinese University of Hong Kong) — Principal investigator
First posted
Mar 8, 2023
Start date
Sep 1, 2022
Primary completion
Mar 31, 2027 (estimated)
Completion
Mar 31, 2027 (estimated)
Last update
Sep 1, 2026

Study contacts

Ka Pang Chan, MBChB
Contact
chankapang@cuhk.edu.hk
35052211
David SC Hui, MD
study director · Chinese University of Hong Kong

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion